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The Role of Cardiovascular Magnetic
Resonance Imaging in Heart Failure
Theodoros D. Karamitsos, MD, PHD,* Jane M. Francis, DCC(R), DNM,* Saul Myerson, MD,*
Joseph B. Selvanayagam, MBBS, DPHIL,† Stefan Neubauer, MD*
Oxford, United Kingdom; and Adelaide, Australia
Noninvasive imaging plays a central role in the diagnosis of heart failure, assessment of prognosis, and monitor-
ing of therapy. Cardiovascular magnetic resonance (CMR) offers a comprehensive assessment of heart failure
patients and is now the gold standard imaging technique to assess myocardial anatomy, regional and global
function, and viability. Furthermore, it allows assessment of perfusion and acute tissue injury (edema and necro-
sis), whereas in nonischemic heart failure, fibrosis, infiltration, and iron overload can be detected. The informa-
tion derived from CMR often reveals the underlying etiology of heart failure, and its high measurement accuracy
makes it an ideal technique for monitoring disease progression and the effects of treatment. Evidence on the
prognostic value of CMR-derived parameters in heart failure is rapidly emerging. This review summarizes the
advantages of CMR for patients with heart failure and its important role in key areas. (J Am Coll Cardiol 2009;
54:1407–24) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.094c
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aeart failure (HF) is associated with significant morbidity,
ortality, and financial burden to health care services (1). In
he U.S., around 5,700,000 people, representing 2.5% of
mericans older than 20 years of age, have been diagnosed
ith this condition (2). The aging of the population and the
mproved prognosis of patients with acute coronary events
urther fuel the HF epidemic. Consequently, hospital dis-
harges in the U.S. for HF increased from 877,000 in 1996
o 1,106,000 in 2006 (13% increase) (2).
The early diagnosis and identification of the underlying
tiology of HF is of paramount importance, because although
he general treatment is common to many patients, some
auses require specific treatment and may be correctable.
oninvasive imaging plays a central role in the diagnosis of
F, the assessment of prognosis, and monitoring of therapy.
he recently updated American College of Cardiology/
merican Heart Association guidelines (3) note that when
maging techniques are used to assess patients with HF, 3
undamental questions must be addressed: 1) Is the left
entricular (LV) ejection fraction preserved or reduced? 2) Is
he structure of the LV normal or abnormal? 3) Are there other
tructural abnormalities such as valvular, pericardial, or right
entricular (RV) abnormalities that could account for the
rom the *University of Oxford Centre for Clinical Magnetic Resonance Research,
epartment of Cardiovascular Medicine, John Radcliffe Hospital, Oxford, United
ingdom; and the †Department of Cardiovascular Medicine, Flinders Medical
entre, Adelaide, Australia. Funded by the British Heart Foundation, the UK
edical Research Council, the National Institute for Health Research Biomedical
esearch Centre Programme, and Heart Research UK.(
Manuscript received February 25, 2009; revised manuscript received April 14,
009, accepted April 28, 2009.linical presentation? Two-dimensional echocardiography is
urrently the imaging modality most commonly used to answer
hese questions, and will remain so for the foreseeable future. It
rovides a good general assessment of LV function but is
imited in patients with poor acoustic windows, it requires
eometric assumptions in quantifying global LV systolic func-
ion, and its ability to provide specific tissue characterization is
odest.
Cardiovascular magnetic resonance (CMR) is a rapidly
volving technology that is increasingly being used for the
oninvasive imaging of the expanding HF population. In
his review we discuss: 1) how CMR works; 2) what type of
nformation CMR can provide in patients with HF, with
articular emphasis on its ability to accurately subclassify
uch patients; and 3) what the expanding role of CMR is for
rognostic evaluation in the HF population.
ow Does CMR Work?
urrently, CMR is generally performed at a magnetic field
trength of 1.5-T, which is around 30,000 times stronger than
he earth’s magnetic field (more recently, 3.0-T magnets are
ncreasingly being used). This powerful magnetic field is used
o align the nuclear magnetization of hydrogen atoms, which
re abundant in the human body. These hydrogen nuclei are
hen excited intermittently by pulses of radiofrequency waves (a
agnetic resonance [MR] sequence), and the signal emitted
rom the body in return is detected with MR receiver coils. In
R imaging, signal from a given tissue (e.g., heart muscle, fat,
nd so on) is determined by its density of hydrogen atoms
proton density), and by 2 distinct MR relaxation parameters,
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CMR in Heart Failure October 6, 2009:1407–24longitudinal relaxation time (T1)
and transverse relaxation time
(T2). Proton density, T1, and T2
can vary substantially for different
tissues, and these differences are
used to generate contrast in MR
images. Image contrast can also be
modified by modulating the way
the radiofrequency pulses are
played out (the MR sequence). For
example, in so-called T1-weighted
images, myocardial tissue is dark,
whereas fat is bright. On the other
hand, T2-weighted images high-
light unbound water in the myocar-
dium and are used to show myocar-
dial edema caused by inflammation
or acute ischemia (4).
A CMR sequence consists of a
series of radiofrequency pulses,
magnetic gradient field switches,
and timed data acquisitions, all
applied in a precise order to gen-
rate the CMR image. Spin echo sequences are mainly used
or anatomic imaging and tissue characterization. Gradient
cho sequences show fat and blood as white and can be used
o acquire cine images. The most recent standard cardiac
R sequences are steady-state free precession, which pro-
ide the best contrast between chamber blood (white) and
yocardium (dark), and these are now routinely used for
maging of cardiac function. Fat suppression sequences
llow signal from fat to be specifically suppressed with
pecial pre-pulses. Several other approaches exist, and CMR
equence development is a rapidly evolving field. However,
detailed description of this is beyond the scope of this
eview.
To prevent artifacts from cardiac motion, most CMR
mages are generated with fast sequences gated to the
-wave of the electrocardiogram. Respiratory motion, an-
ther source of artifacts, is usually eliminated by acquiring
MR images in end-expiratory breath-hold.
For infarct/fibrosis imaging, intravenous gadolinium-
helated contrast agents, such as gadolinium diethylenetri-
mine penta-acetic acid are needed. The physiological basis
f late gadolinium enhancement (LGE) is an increase in its
olume of distribution within areas of scarring or fibrosis
nd an abnormally prolonged washout related to decreased
unctional capillary density in the irreversibly injured myo-
ardium (5–8). The regional increase in extracellular volume
vailable for gadolinium distribution produces T1 shorten-
ng, which manifests as hyperenhancement (high signal) in
reas of abnormality on so-called inversion-recovery CMR
mages: by “nulling” the normal myocardial signal, the area
f myocardial injury appears extremely bright, with high
Abbreviations
and Acronyms
ARVC  arrhythmogenic
right ventricular
cardiomyopathy
CAD  coronary artery
disease
CMR  cardiovascular
magnetic resonance
CRT  cardiac
resynchronization therapy
DCM  dilated
cardiomyopathy
HCM  hypertrophic
cardiomyopathy
HF  heart failure
LGE  late gadolinium
enhancement
LV  left ventricular
MR  magnetic resonance
RV  right ventricularignal contrast relative to the black normal myocardium. tFor perfusion imaging, the dynamic passage of a
adolinium-based contrast bolus is followed through the
ardiac chambers and the myocardium. Pharmacologic va-
odilation (with adenosine or dipyridamole) induces a 3- to
-fold increase of blood flow in myocardial areas subtended
y normal coronary arteries, whereas no (or only minimal)
hange is found in areas subtended by stenotic coronary
rteries. Thus, contrast arrival in these areas is delayed, and
hey therefore appear hypointense (dark) compared with
djacent normal myocardium.
MR Safety
he CMR scan subjects and operators are not exposed to
onizing radiation, and there are no known detrimental bio-
ogical side effects of MR imaging if safety guidelines are
ollowed (9). However, only trained staff should have access to
he magnet room, because any iron-based item with ferromag-
etic properties can be pulled into the magnet’s core at high
peed, potentially causing serious injury and damage. Patients
ith implanted electronic devices such as pacemakers or
efibrillators are generally not accepted for CMR scanning (9),
lthough this may change in the future with further technical
evelopment (MR-compatible pacemakers, and so on). Some
eurological devices such as cerebrovascular clips continue to
ose a problem, as do metallic objects in delicate positions, e.g.,
ithin the eye. Generally, most medical metallic implants are
afe in a CMR environment, including nearly all prosthetic
ardiac valves, coronary and vascular stents, and orthopedic
mplants. However, whenever there is uncertainty regarding
particular device or implant, its CMR safety status should
e checked by referring to information provided by the
anufacturer.
Gadolinium-based contrast agents have recently been
inked with a rare multisystemic fibrosing disorder of
nknown etiology called nephrogenic systemic fibrosis (10).
he patients at risk of developing this disease are those with
cute or chronic severe renal insufficiency (glomerular fil-
ration rate 30 ml/min/1.73 m2) or renal dysfunction
aused by the hepatorenal syndrome or in the perioperative
iver transplantation period (11). In the latter 2 conditions,
he risk applies to any severity of renal dysfunction. At
resent, there is no evidence that immediate hemodialysis
rotects against nephrogenic systemic fibrosis. Therefore, in
igh-risk patients, gadolinium-based contrast media should
e avoided unless the diagnostic information is essential and
ot available from noncontrast enhanced CMR or other
maging modalities. It should be mentioned that
adolinium-based contrast agents are not approved by the
.S. Food and Drug Administration for use in cardiac
tudies in the U.S.
hat Are the Imaging Questions
n HF That CMR Has to Answer?
here are a number of important questions that CMR has
o address. For example, what is the extent of LV and RV
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October 6, 2009:1407–24 CMR in Heart Failurelobal and regional dysfunction and dilation, what is the
nderlying etiology of HF, and can modifiable components
f the disease process be identified?
Unlike echocardiography, CMR has the ability to image
n any desired plane and with a nearly unrestricted field of
iew, allowing unprecedented flexibility to evaluate abnor-
al cardiac and extracardiac structures. The functional
nformation derived from cine CMR includes global LV
nd RV volumes and mass, without the need to make any
eometrical assumptions, and therefore applies to ventricles
f all sizes and shapes, even to those that have been
xtensively remodeled (12,13). Importantly, all major CMR
echniques (e.g., volume and mass assessment with cine
maging, identification and quantification of fibrosis/
carring, quantification of valvular lesions) are not only
ighly accurate but also very reproducible (14–16). More-
ver, the inherent 3-dimensional nature of CMR makes it
articularly well suited to studying the RV, which is difficult
o assess with echocardiography because of its complex and
ariable morphology. With regard to regional ventricular
unction, CMR enables the accurate identification of even
ubtle regional wall motion abnormalities with the use of
teady-state free-precession sequences, which provide excel-
ent delineation of the blood–myocardium interface (17).
hese sequences also enable the evaluation of valve struc-
ure, although valve morphology is generally better assessed
y echocardiography. Although that technique is the stan-
ard tool for initial assessment and longitudinal evaluation
f patients with valvular heart disease, CMR is an attractive
lternative, particularly in subjects with poor acoustic win-
ows. For flow assessment, velocity-encoding CMR se-
uences, which enable accurate quantitative measurements
or stenotic (peak velocity and by applying the Bernoulli
quation peak gradient) and regurgitant valvular lesions
regurgitant volume and fraction), are used (18). Further-
ore, when a shunt is suspected, the pulmonary-to-
ystemic flow ratio (Qp/Qs) can be determined by measur-
ng flow in the main pulmonary artery and the ascending
orta.
Specific CMR sequences (T1- or T2-weighted as de-
cribed previously) can enable myocardial tissue character-
zation, based on the different relaxation properties of tissues
uch as fat, muscle, and areas of inflammation. Intracardiac
hrombi can also be detected using images acquired early (1
o 3 min) after gadolinium administration with inversion
ecovery sequences (so-called early gadolinium imaging).
mages acquired later (5 to 20 min after 0.1 to 0.2 mmol/kg
adolinium injection) using the same sequences constitute
he LGE-CMR technique. The development of this tech-
ique has substantially expanded the role of CMR in the
valuation of HF patients. Viability/post-myocardial infarc-
ion scarring can be described with unprecedented resolu-
ion, and highly specific patterns of fibrosis and scarring
ave been described for many nonischemic cardiomyopathic
rocesses, providing valuable diagnostic and pathophysio-ogical insights (Fig. 1) (7,19). Furthermore, several other tMR techniques such as first-pass perfusion with or with-
ut vasodilator stress, and MR angiography are used on an
ndividual case basis depending on the clinical history.
Nearly one-half of HF patients have abnormalities in
iastolic function with preserved ejection fraction (20).
MR can assess diastolic function in several ways. In a
anner analogous to echocardiography, velocity encoding
MR can measure early diastolic (E) and atrial systolic (A)
eak flow velocities and E/A ratios of the mitral inflow (21).
urthermore, time–volume curves generated from retro-
pectively gated cine images provide indexes of global
iastolic function, such as peak filling rate and time to peak
lling rate (22). Magnetic resonance tagging is a sophis-
icated method for quantitative analysis of regional sys-
olic and diastolic function. Selective saturation pre-
ulses are used to superimpose a grid across the field of
iew. The grid lines are deformed by myocardial contrac-
ion, strain, and torsion, allowing direct quantification of
yocardial deformation and strain (23). Although all of these
MR techniques provide useful information on diastolic
unction, they are limited by relatively complex and time-
onsuming post-processing compared with echocardiography,
hich remains the standard technique for assessment of
iastolic function (24).
The ability of CMR to provide a specific diagnosis on a
ubstantial proportion of HF patients enables the physician
o choose the best management strategy tailored to the
atient’s imaging findings. Moreover, CMR is ideally suited
o monitor treatment and disease progression, because of
igh measurement accuracy/reproducibility and because pa-
ients can undergo serial CMR scans without exposure to
onizing radiation.
The identification of prognostic markers in patients with
F of either ischemic or nonischemic etiology is of para-
ount importance in the era of evidence-based cardiology.
ophisticated therapeutic options such as implantable
ardioverter-defibrillators and biventricular pacemakers are
ow available, and the identification of patients who benefit
ost from these expensive therapies is becoming an increas-
ng necessity.
MR and Specific Causes of HF
he CMR techniques described above, and particularly the
evelopment of LGE-CMR, have revolutionized the role of
MR in the evaluation of HF patients. Currently, a
omprehensive CMR protocol including anatomy, function,
nd LGE imaging is able to identify the underlying etiology
n a substantial proportion of HF patients.
schemic cardiomyopathy. VIABILITY. Ischemic cardio-
yopathy is characterized by areas of scarring that typically
nvolve the subendocardium, and depending on the size of
he infarct, extend up to the epicardium in a pattern
onsistent with the “wave front phenomenon” of ischemic
ell death (25). With the development and extensive his-
opathological validation of the LGE technique, CMR has
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CMR in Heart Failure October 6, 2009:1407–24ecome the noninvasive gold standard modality for visual-
zing irreversibly injured myocardium (Fig. 2) and assess its
ransmural extent (26,27). The superb spatial resolution of
GE-CMR allows the detection of even small subendocar-
ial infarcts that might otherwise be missed by lower spatial
esolution techniques such as single-photon emission com-
uted tomography (28). The ability of LGE-CMR to
redict segmental functional recovery post-revascularization
as a major breakthrough. In a seminal paper, Kim et al.
29) showed an inverse relationship between the transmural
xtent of myocardial infarction and recovery of segmental
ontractile function after revascularization. Multiple studies
ave confirmed the ability of LGE-CMR to predict recov-
ry of contractile function post-revascularization in both the
Figure 1 HE Patterns for Ischemic and Nonischemic Disorders
A schematic representation of hyperenhancement (HE) patterns that are character
diomyopathy always involves the subendocardium. In contrast, midwall or epicardi
et al. (19). HTN  hypertension.cute and the chronic infarct setting (30,31). Although come uncertainty exists regarding the predictive value of
GE-CMR in segments with an intermediate (25% to
5%) transmural extent of scarring, overall, LGE-CMR has
he major advantage of assessing viability without the need
o stress the patient, and thus has become the routine CMR
rocedure for this indication (32). A low-dose dobutamine
tudy may be helpful in equivocal cases, but in practice this
s rarely needed (33,34).
LGE-CMR not only defines the location and extent of
nfarction, but also differentiates areas that show failure of
issue perfusion after revascularization, the so-called no-
eflow phenomenon. Extensive microcirculatory damage,
yocyte necrosis, and localized edema that compresses
ntramural vessels result in delayed penetration of the
r ischemic and nonischemic disorders. Note that the area of HE in ischemic car-
trongly suggests a nonischemic etiology. Reprinted, with permission, from Shahistic fo
al HE sontrast to the core of the infarction. This generates a
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October 6, 2009:1407–24 CMR in Heart Failureentral black area within a larger surrounding region of
yperenhancement (Fig. 3). Such microvascular obstruction
etected by CMR has been linked to aggravated ventricular
emodeling and adverse cardiovascular events after acute
yocardial infarction (35,36).
EVERSIBLE VERSUS IRREVERSIBLE INJURY. The combina-
ion of LGE and T2-weighted imaging enables CMR to
ifferentiate between acute and chronic injury. In acute
yocardial infarction, T2-weighted images can detect an
rea of high signal caused by tissue edema that exceeds that
f irreversible injury (37) and represents the area at risk.
urthermore, edema imaging detects acute ischemic myo-
yte injury before the onset of irreversible myocyte injury
38). This type of imaging is particularly appealing because
t allows the detection of the extent of the ischemic zone
Figure 2 Three Characteristic Examples of Late Gadolinium Enh
(A) Ischemic cardiomyopathy: previous myocardial infarct with transmural extent o
the inferolateral region (black arrows). (B) Myocarditis: midwall late enhancement
olinium enhancement in the septum (white arrows).
Figure 3 Microvascular Obstruction on
Late Gadolinium Enhancement Imaging
A patient with recent myocardial infarction and evidence of microvascular
obstruction on late gadolinium enhancement imaging. Note the hypoenhanced
(black) area in the lateral wall (black arrows) completely surrounded by hyper-
enhanced regions.pven when the coronary artery is reperfused (39). Thus,
MR has an unprecedented capability to visualize the
mount of salvaged myocardium, and this can be achieved
etrospectively as late as 3 days after the insult. This method
eralds a new era of clinical trials on salvage strategies in
rimary percutaneous coronary intervention. In clinical
ractice, T2-weighted imaging improves the overall accu-
acy of CMR in identifying patients with acute coronary
yndromes (40). Edema imaging is an application that still
eeds further validation and refinement, however, to opti-
ize both acquisition and quantitative analysis. Traditional
dema-sensitive CMR methods using turbo spin-echo se-
uences are limited by artifacts leading to false-negative
e.g., posterior wall signal loss caused by through-plane
otion) or false-positive results (bright rim artifacts caused
y stagnant blood along the endocardial surface) (41). To
vercome these problems, bright blood T2-weighted meth-
ds have been developed that increase the diagnostic accu-
acy and improve the reliability of CMR edema imaging
41,42).
THER SEQUELAE OF MYOCARDIAL INFARCTION. Compli-
ations of myocardial infarction, such as LV mural throm-
us and aneurysmal dilation, can readily be recognized with
MR (43,44). Although small thrombi may be visible on
ine images, confirmation on early post-contrast images is
ecommended. Thrombi are avascular structures, and hence
n inversion recovery images acquired post-contrast appear
s low-signal-intensity masses surrounded by high-signal-
ntensity areas such as cavity blood and/or hyperenhanced
yocardial scar (Fig. 4) (43). The 3-dimensional shape and
yskinesis of true and false aneurysms can be reliably
etected by cine CMR. Other complications of infarction,
uch as papillary muscle involvement causing mitral regur-
itation and rupture of the interventricular septum, can also
e characterized by CMR.
TRESS-INDUCIBLE ISCHEMIA. Multiple studies have
ment
ing (white arrows) in the inferior wall, but only subendocardial (50%) scar in
inferolateral wall (white arrows). (C) Dilated cardiomyopathy: midwall late gad-ance
f scarr
in theroven the clinical feasibility, safety, and high diagnostic
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CMR in Heart Failure October 6, 2009:1407–24ccuracy of first-pass perfusion CMR with vasodilator stress
or the detection of coronary artery disease (CAD) (45–50).
recent meta-analysis of 14 single-center studies (1,183
atients) showed a pooled sensitivity of 91% and specificity
f 81% compared with conventional X-ray coronary angiog-
aphy (45). A multicenter, multivendor trial recently showed
hat adenosine CMR perfusion is a valuable alternative to
ingle-photon emission computed tomography for CAD
etection showing at least equal diagnostic performance in a
ead-to-head comparison (51). Dobutamine stress CMR is
n alternative technique for detecting CAD. Its safety and
igh diagnostic accuracy have been proven in several single-
enter studies (52,53). Patients with poor echo windows can
e readily studied with a CMR dobutamine protocol (54).
ORONARY IMAGING. Imaging of the coronary arteries is
ot a standard clinical application of CMR. The small size
nd tortuous course of the coronary arteries, which move
apidly because of cardiac contraction and respiratory mo-
ion, make MR coronary angiography a demanding tech-
ique. Very high spatial and temporal resolution is required
or this application, and although some progress has been
ade, reliable assessment of coronary stenoses by CMR is
till challenging, with sensitivity and specificity showing a
ide range: 50% to 94% and 50% to 100%, respectively (55).
onsequently, the most recent clinical guidelines only
upport the use of CMR coronary angiography for the
dentification of anomalous coronary artery origins (55).
ilated cardiomyopathy (DCM). The differentiation be-
ween ischemic and nonischemic causes of HF is a common
hallenge in clinical practice. The demonstration of normal
oronary arteries on angiography is not sufficient on its own
o exclude CAD as the underlying cause of HF. CMR, and
n particular the LGE technique, is useful to determine
hether LV dysfunction has an ischemic etiology. Up to
3% of patients diagnosed with DCM show areas of
Figure 4 Large Apical Thrombus in a Patient With Recent Tran
Images acquired early (1 to 3 min) (A) and late (10 min) (B) after gadolinium ad
intracavitary thrombus within the left ventricular apex (black arrows) in a patient wubendocardial or transmural LGE strongly suggestive of mrior infarction (56,57). This may be caused by spontaneous
ecanalization after an occlusive coronary event, vasospasm,
r embolization from minimally stenotic but unstable
laque. CMR has high sensitivity (81% to 100%) to detect
nderlying CAD in patients with poor LV function (56,58).
n contrast, 10% to 26% of DCM patients without features
f infarction show patchy or longitudinal striae of midwall
yperenhancement unrelated to a particular coronary artery
erritory (Fig. 2) (56,58). This distinct pattern of LGE
orresponds to focal fibrosis at autopsy (59). It should be
orne in mind that the total absence of LGE does not
ompletely rule out ischemic cardiomyopathy in the rare
etting of global myocardial hibernation. Multiple studies
ave now confirmed the use of CMR as a powerful tool for
lassifying patients with HF and LV systolic dysfunction
ith regard to the presence or absence of underlying CAD
57,58). Moreover, LGE-CMR can help to identify the
rrhythmogenic substrate and plan an appropriate mapping
nd ablation strategy in patients with DCM (60).
yocarditis. Acute myocarditis may present as new-onset
F, and its diagnosis is usually one of exclusion. The
ltimate proof that the patient has myocarditis may be
rovided by endomyocardial biopsy, but the patchy nature
f the disease increases the sampling error and limits its
iagnostic role. Friedrich et al. (61) were the first to propose
MR for the noninvasive diagnosis of acute myocarditis.
sing T1-weighted images, they found that the myocar-
ium in patients with suspected myocarditis often has
igher signal intensity relative to skeletal muscle (61). More
ecently, Abdel-Aty et al. (62) reported that a combined
MR approach using T2-weighted images and LGE pro-
ides high diagnostic accuracy for the identification of
atients with acute myocarditis. The T2-weighted images
arly after symptom onset may show subepicardial and
idwall areas of increased signal defining focal areas of
l Anterior Infarct
ration showing a large
large transmural anterior infarct (white arrows).smura
minist
ith ayocardial edema. The LGE pattern in the setting of
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October 6, 2009:1407–24 CMR in Heart Failureyocarditis has a characteristic distribution (Fig. 2), and
mportantly, has been shown to have additional value in the
etection of active myocarditis as defined by histopathology
63). The subepicardium is usually affected with varying
egrees of progression toward the midmyocardial wall and
ypical sparing of the subendocardium, and the lateral and
nferolateral walls are frequently involved (64). A different
attern of midwall septal LGE has been associated with
uman herpesvirus 6 or combined herpesvirus 6/Parvo B19
yocarditis (64). Although the presence of a typical LGE
attern is a strong indicator of the diagnosis, the absence of
his pattern does not absolutely exclude myocarditis. The
ocal areas of hyperenhancement become diffuse over a
eriod of days to weeks, then decrease during healing, and
ecause of shrinking, may become invisible after recovery
63). Alternatively, large areas of scarring may still be visible
fter healing, causing distinctive linear midwall striae of
yperenhancement, a pattern similar to that seen in DCM
atients (65). This finding suggests that previous myocar-
itis may be the underlying cause of LV dysfunction in a
roportion of patients with DCM. Finally, CMR-guided
ndomyocardial biopsy may result in a higher yield of
ositive findings than routine RV biopsy (63).
ypertrophic cardiomyopathy (HCM). HCM shows a
ide variation of phenotypic expression. Asymmetric in-
olvement of the interventricular septum is the most com-
on form of the disease. Other variants include symmetric,
pical, and mass-like LV hypertrophy. Some patients
rogress to an end-stage form, known as the burned-out
hase, which is characterized by progressive wall thinning
nd systolic dysfunction. CMR has the ability to evaluate
he heterogeneous appearances of HCM better than any
ther imaging modality (66–68). It can define the site of
ypertrophy, allowing the visualization of areas difficult to
ssess with echocardiography, such as the posterolateral wall
r the apex, and determine precisely the extent of hypertro-
hy (67–69). Moreover, echocardiography may underesti-
ate the magnitude of LV hypertrophy (in one study
eported as maximal wall thickness 24  3 mm by echo-
ardiography versus 32  1 mm by CMR), which may be
elated to the difficulty of reliably imaging all segments (67).
his is important clinically given that maximal wall thick-
ess 30 mm is a major prognostic indicator in these
atients (70). CMR is also useful in assessing papillary
uscle abnormalities in HCM (anteroapical displacement
r double bifid papillary muscles) that have been associated
ith LV outflow track obstruction independent of wall
hickness (71).
Crucially, LGE-CMR identifies foci of diffuse scarring
hat may exist not only in severely hypertrophied myocar-
ium but also (although less frequently) in regions with
ormal wall thickness (67). The pattern of LGE in HCM is
atchy, typically midwall, and commonly involves the
V–RV junctions (Fig. 5) (72). It may also involve the apex
n the apical variant of the disease (73). An exception to the
atchy nature of LGE in HCM is in areas of burned-out fiyocardium, where the LV wall is typically thinned and
nhancement may be full thickness. Although this resem-
les the pattern of LGE in patients with chronic transmural
yocardial infarction, in burned-out HCM the areas of
brosis typically do not conform to a particular coronary
rtery territory (74). Histopathological CMR correlation
tudies strongly relate the presence of hyperenhancement in
CM to areas of increased collagen deposition (75). Clin-
cal studies have reported CMR-detected rates of fibrosis in
p to 80% of HCM patients studied, with the variation
cross studies probably accounted for by the widely variable
atient populations studied (76,77) and the limitations of
etection in very diffuse fibrosis. The incidence of myocar-
ial fibrosis increases with increasing wall thickness, and
asodilator reserve is reduced, particularly in the endocar-
ium, and in proportion to the magnitude of hypertrophy
78). Finally, an important underappreciated feature of
CM, the presence of LV apical aneurysms, has been
ecently identified by CMR and linked with a high rate of
dverse events (79).
rrhythmogenic right ventricular cardiomyopathy
ARVC). ARVC is an inherited disease characterized by
nlargement, dysfunction, and fibrofatty replacement of the
V (80). Biventricular disease variants have also been
ecognized, and in some cases, the LV may be the predom-
nantly affected chamber (81,82). ARVC has a broad clinical
pectrum and may present with ventricular tachyarrhyth-
ias, sudden death, or HF. Its diagnosis is based on a set of
ajor and minor criteria and generally requires an inte-
rated assessment of electrical, functional, and anatomic
bnormalities. Echocardiography and CMR are the most
ommonly used imaging modalities in the diagnostic
orkup of this entity. Compared with echocardiography,
MR can better visualize the RV in multiple planes (axial,
agittal, short-axis, and RV long-axis orientation) and
etect both functional and structural features of ARVC.
unctional abnormalities include regional wall motion de-
ects, focal aneurysms, global RV dilation, and dysfunction
Fig. 6, Online Video 1) (83). The morphological abnor-
alities include focal wall thinning, wall hypertrophy,
rabecular hypertrophy and disarray, moderator band hyper-
rophy, RV outflow tract enlargement, and intramyocardial
atty infiltration (84). Of these, localized aneurysms, severe
lobal/segmental RV dilatation, and global systolic dysfunc-
ion are considered major criteria, whereas mild global/
egmental dilatation of the RV, regional contraction abnor-
alities, and global diastolic dysfunction are considered
inor criteria according to the task force (85). Recent
tudies have highlighted the role of CMR in detecting
brosis of the RV myocardium in patients with ARVC
86,87). The presence of LGE correlates well with
brofatty replacement on endomyocardial biopsy and
redicts inducible ventricular tachycardia during electro-
hysiological studies, which may have important impli-
ations for risk stratification (86). The detection of
brofatty replacement is difficult, however, because of its
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CMR in Heart Failure October 6, 2009:1407–24iffuse nature, mixing with normal myocardial tissue and
he thin RV wall combined with partial volume effects.
he identification of fatty infiltration in the RV wall
sing T1-weighted images (with and without fat suppres-
ion) is not a Task Force criterion, has poor sensitivity
nd specificity, and is in fact the least reproducible CMR
arameter (88). In contrast, the detection of global and
egional RV wall motion abnormalities is highly specific
o the disease (88). However, experience is needed and
aution should be exercised in interpreting results, espe-
ially in the absence of wall motion abnormalities. It
hould also be borne in mind that regions close to the
oderator band may show contraction abnormalities,
hich in isolation do not represent findings positive for
RVC. Despite the controversies surrounding its role in
RVC, CMR is a valuable diagnostic tool that substan-
ially improves the sensitivity of clinical diagnosis, par-
icularly in early or incompletely expressed disease (89).
ron overload cardiomyopathy. Heart failure caused by
ron overload is the leading cause of death in patients with
eta-thalassemia major (90). Cardiac siderosis can also be
ound in other transfusion-dependent anemias and in pri-
Figure 5 Example of a Patient With Hypertrophic Cardiomyopat
(A) Still frame from horizontal long-axis cine sequence showing marked septal hyp
areas of scarring in the hypertrophied septum (black arrows). (C) Still frame from
hypertrophy. (D) Same short-axis view with late gadolinium enhancement imaging
right ventricular junctions (black arrows).ary hemochromatosis. The cardiomyopathy is reversible if chelation is commenced early, but diagnosis is often delayed
ecause of the late onset of symptoms. Myocardial iron
verload can be quantitatively assessed by T2* CMR imag-
ng, with profound implications for the clinical management
f these patients (91,92). T2* is a parameter related to but
istinct from T2 that decreases when regional magnetic
eld homogeneity is reduced in the vicinity of iron. In
ontrast, there is no significant correlation between myo-
ardial T2* and the conventional parameters of iron status,
uch as serum ferritin or liver iron load (91). As myocardial
ron increases, there is a progressive decline in ejection
raction and all patients with HF have a myocardial T2* of
20 ms. This is useful to guide treatment and monitor
esponse to iron-chelating drug regimens (93,94).
myloidosis. Cardiac involvement in systemic amyloidosis
s frequent. The heart in AL amyloidosis (the most common
orm) is affected in up to 50% of cases, and congestive HF
s the presenting clinical manifestation in about one-half of
hese patients (95). Once congestive HF occurs, the median
urvival is 6 months in untreated patients; therefore, early
ecognition of the disease and prompt initiation of therapy
s critical. Characteristic structural and functional features of
hy. (B) Same view with late gadolinium enhancement imaging showing patchy
rt-axis cine sequence of the same patient illustrating the asymmetric septal
g the marked diffuse fibrosis within the thickened septum involving both left andhy
ertrop
a sho
showinardiac amyloidosis can be detected by CMR imaging, such
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October 6, 2009:1407–24 CMR in Heart Failures concentric hypertrophy with normal or reduced contrac-
ility, thickened interatrial septum, and bi-atrial dilation
95). After gadolinium administration, there may be a
ircumferential pattern of LGE, preferentially affecting the
ubendocardium but sometimes showing a more patchy
ransmural pattern (Fig. 7) (95–97). The wash-in and
ashout kinetics of gadolinium are markedly abnormal
hen amyloid fibrils are accumulated in the myocardial
nterstitium, which results in unique LGE appearances.
here may be a characteristic zebra-stripe appearance with
ubendocardial enhancement of the LV and RV endocar-
ium, sparing the midwall of the interventricular septum.
he blood pool appears atypically dark, reflecting high
yocardial contrast uptake and fast blood pool washout.
he LGE-CMR and cardiac biopsy findings were corre-
ated in a study of 33 patients presenting with diastolic HF
n combination with either myocardial hypertrophy and/or
ther conditions often associated with cardiac amyloidosis
98). A typical pattern of circumferential subendocardial
GE was observed in 12 of 15 patients (sensitivity 80%)
ith subsequent biopsy-proven cardiac amyloidosis, com-
ared with only 1 individual in the group of 18 patients
specificity 94%) diagnosed with other myocardial diseases.
lthough cardiac involvement is considered a late manifes-
ation of systemic amyloidosis, in 11 of 15 patients with
ositive biopsy, cardiac involvement was the first manifes-
ation of disease (98). This may in part reflect the ability of
GE-CMR to detect early cardiac involvement when mor-
hological changes are not apparent by echocardiography or
uclear techniques.
arcoidosis. Myocardial involvement occurs in at least 25%
f patients with sarcoidosis at autopsy. However, fewer than
ne-half of them have signs or symptoms of cardiac involve-
ent (99,100), making antemortem diagnosis of cardiac
Figure 6 Example of a Patient With Arrhythmogenic Right Vent
Still frames from a horizontal long-axis cine sequence in end diastole (A) and end
(B) showing prominent aneurysmal areas in the right ventricular free wall (white aarcoidosis an exceptional challenge. Progressive congestive cF has been shown to be the cause of death in 25% of
atients with cardiac sarcoidosis, making it the second most
requent cause of death after sudden death caused by
rrhythmias (101,102). Thus, it is important to identify the
resence of cardiac involvement in these patients who may
enefit from medical and/or implantable defibrillator ther-
py. Cardiovascular MR can show some of the characteristic
eatures of cardiac sarcoid (e.g., septal thinning, LV/RV
ilation and systolic dysfunction, or pericardial effusion)
Fig. 8) (101,103). Moreover, several studies have shown
he usefulness of LGE-CMR in the detection of cardiac
arcoidosis and evaluation of response to steroid treatment
104,105). The LGE in these patients usually shows a
onischemic pattern with hyperenhancement of the mid-
yocardial wall or the epicardium in an unpredictable
istribution (7). However, subendocardial or transmural
yperenhancement has also been observed, mimicking an
schemic pattern. The anteroseptal and inferolateral walls
re most frequently involved, although sometimes hyperen-
ancement is seen in other territories, including the RV
106). Follow-up studies showed that the enhanced areas
ere notably diminished in size and intensity after steroid
reatment (107). The LGE-CMR scan can also be used to
uide endomyocardial biopsy in sarcoidosis. Additionally,
2-weighted sequences may monitor disease activity by the
dentification of edematous areas associated with inflamma-
ion and granulomatous lesions (108).
nderson-Fabry disease. Anderson-Fabry disease is an
-linked disorder of lysosomal metabolism caused by the
artial or complete deficiency of the enzyme alpha-
alactosidase A, which results in the accumulation of excess
ellular glycosphingolipid within the blood vessels and heart
109). This is a cause of LV hypertrophy associated with
rogressive myocardial fibrosis and death from HF. CMR
r Cardiomyopathy
e
. See also Online Video 1.ricula
systol
rrows)an be used to assess LV function, determine the pattern
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CMR in Heart Failure October 6, 2009:1407–24nd extent of LV hypertrophy, and identify areas of fibrosis.
he LGE pattern typically spares the subendocardium and
hows a striking predilection for the basal inferolateral LV
egments. Histological data suggest that these areas of LGE
Figure 7 Example of a Patient With Cardiac Amyloidosis
Still diastolic frames from cines: vertical long- (A) and short-axis at the midventric
images using the late gadolinium enhancement technique, respectively. The vertic
the left ventricle (white arrows) and atrium (white arrowheads). The short-axis im
arrows). The septum shows biventricular subendocardial enhancement with a dark
ventricle (white arrowheads). Note the dark blood pool.
Figure 8 Example of a Patient With Sarcoidosis
(A) Still frame from short-axis cine sequence showing an area of marked thinning
ferent patterns of fibrosis. Transmural hyperenhancement corresponding to the are
right ventricular insertion point (white arrow), and midwall enhancement in the inforrespond to regions of replacement fibrosis (110). Up to
% of patients who are initially diagnosed with HCM
ctually have evidence of Anderson-Fabry disease (111).
he implications of an incorrect diagnosis are considerable
vel (C) showing moderate concentric hypertrophy. (B and D) Corresponding
-axis image (B) shows diffuse, predominantly subendocardial enhancement in
) shows a ring of subendocardial hyperenhancement in the left ventricle (white
all (zebra appearance). There is also widespread hyperenhancement in the right
anterior septum. (B) Same view after gadolinium administration showing 3 dif-
eptal thinning (black arrows), subepicardial hyperenhancement in the inferior
ral wall (white arrowheads).ular le
al long
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October 6, 2009:1407–24 CMR in Heart Failureecause patients with Anderson-Fabry disease respond to
nzyme replacement therapy, including an improvement in
ardiac function and regression of hypertrophy (112,113).
deally, the administration of recombinant alpha-
alactosidase A should be started before myocardial fibrosis
as developed to achieve long-term improvement in myo-
ardial morphology, function, and exercise capacity (114).
nderson-Fabry disease should always be considered if
nexplained LV hypertrophy is seen, particularly in a young
atient.
onstrictive pericarditis. The normal pericardium appears
s a hypointense line usually less than 2 mm thick, and indeed
ometimes not visible on CMR images. CMR can diagnose
onstrictive pericarditis by providing morphological evidence of
n abnormally thickened pericardium associated with constric-
ive physiology (115). On black blood anatomical CMR
mages, a pericardial thickness of more than 4 mm is suggestive
f constriction (Fig. 9). In addition, free-breathing real-time
ine CMR can depict 2 important features: increased ventric-
lar coupling with early inspiratory flattening of the interven-
ricular septum in diastole and dilation of the inferior vena
ava, which shows little change in size during respiration.
hese findings may help differentiate constrictive pericarditis
rom restrictive cardiomyopathy (116). Finally, the use of
agged cine imaging can aid in identifying nonadherence of the
isceral and parietal pericardium throughout the cardiac cycle.
V noncompaction. LV noncompaction is characterized
y prominent LV trabeculations with deep intertrabecular
ecesses, resulting in a distinct noncompacted layer lining
he LV cavity. Echocardiography without contrast may
isdiagnose LV noncompaction as apical HCM (117).
MR can reliably discriminate among apical HCM, mild-
ormal trabeculations, and grossly trabeculated LV myocar-
ium with intertrabecular recesses. A ratio of noncompacted
o compacted myocardium 2.3 yields high sensitivity
Figure 9 Example of a Patient With Pericardial Constriction
(A) T1-weighted spin-echo image showing an area of markedly thickened pericardiu
(B) Real-time free-breathing cine revealed the presence of early inspiratory flatteni85%) and specificity (99%) in the diagnosis of this condi-
ion (118).
hagas disease. Chagas disease is caused by Trypanosoma
ruzi infection. Cardiac involvement is the most serious
ong-term complication, occurring in approximately one-
hird of seropositive individuals, and is a major cause of
eath from HF in Latin America. It is characterized by
rogressive myocardial fibrosis, which can be identified with
GE-CMR in many patients, not only with advanced
isease but also in seropositive subjects without clinical
ymptoms or wall motion abnormalities (119). The LV apex
nd inferolateral regions are the sites where fibrosis is most
ommonly seen. There is an overlap of reported LGE
atterns with both ischemic (subendocardial or transmural)
nd nonischemic patterns (subepicardial, midwall) (119).
dditionally, CMR can detect the consequences of progres-
ive myocardial damage in Chagas disease such as localized
reas of thinning with hypokinesis or akinesis and aneurysm
ormation, with global ventricular dysfunction (120).
ther cardiomyopathies. Other less common myocardial
iseases that result in HF can be identified by CMR.
hurg-Strauss syndrome is a rare form of small-vessel
asculitis that can lead to symptomatic HF with poor
rognosis. In 11 patients with Churg-Strauss syndrome
onfirmed by biopsy, a subendocardial pattern of fibrosis in
he absence of CAD was found (121). Moreover, CMR
llows the detection of endomyocardial fibrosis, providing a
omprehensive tool for the early diagnosis of this rare but
evere disease. The exclusive involvement of endomyocar-
ium on LGE-CMR in conjunction with normal myocar-
ial function, apical obliteration, and thrombus formation
re typical findings in these patients (122). Stress (Tako-
subo) cardiomyopathy is another entity that can be readily
dentified and characterized by CMR. Affected patients
ypically do not show areas of scarring on LGE despite
easuring up to 6 mm, black arrow) overlaying the right ventricular free wall.
he interventricular septum in diastole resulting in a D-shaped left ventricle.m (m
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CMR in Heart Failure October 6, 2009:1407–24haracteristic wall motion defects mimicking anteroapical
nfarction (123,124), but may have evidence of edema on
2-weighted images (125).
ardiac masses. Cardiac masses can occasionally manifest
s new-onset HF (126). CMR imaging with tissue charac-
erization techniques—T2-weighted, T1-weighted, first-
ass perfusion, and LGE—is an ideal method for their
ssessment (Fig. 10, Online Video 2). It provides precise
natomical, functional, and morphological information, in-
luding differentiation from thrombus, often allowing the
pecific diagnosis of the mass (127). Furthermore, CMR has
he ability to differentiate intracardiac masses from masses
hat externally compress the heart and also to show invasion
f surrounding structures.
alvular heart disease. CMR provides information on valve
natomy (although echocardiography is better for assessing
alve structure) and allows excellent quantitative evaluation of
tenosis and regurgitation (18). Importantly, CMR can also
ssess accurately the consequences of the valvular lesion on the
yocardium, including the effects on ventricular volumes and
ass and alterations in systolic function. The high reproduc-
bility of CMR-derived ventricular volumes enables the detec-
ion of modest changes with serial scanning, and can poten-
ially allow earlier identification of LV parameters indicating a
etrimental course. CMR-derived measures of valve dysfunc-
ion (such as regurgitant volume and fraction) may in the
uture become important for planning the correct timing of
alve replacement.
ongenital heart disease. CMR provides a wealth of ana-
omical and physiological information in patients with congen-
tal cardiac abnormalities (128), which are a more rare cause of
F. The detailed description of the use of CMR in such
atients is beyond the scope of this article.
Figure 10 Example of a Patient With a Large Atrial Myxoma
(A) Still frame from horizontal long-axis cine sequence showing the tumor almost
the same view with the mass (black arrow) appearing to prolapse through the mit
sis. The patient presented with dyspnea and had increased systolic pulmonary pre
sion (*). See also Online Video 2.ssessment of
echanical Dyssynchrony With CMR
chocardiography has played a major role in the assessment of
echanical dyssynchrony and the selection of patients for
ardiac resynchronization therapy (CRT). However, despite
he use of sophisticated tools such as tissue Doppler methods
o predict response to CRT, approximately 20% to 30% of
atients do not show clinical improvement (129,130). CMR is
merging as an alternative technique for selecting CRT can-
idates with an increased probability of responding. Mechan-
cal dyssynchrony can be assessed using various CMR tech-
iques, such as cine wall motion, myocardial tagging, tissue
elocity mapping, or displacement imaging (131,132). Recent
tudies have suggested that a large scar burden, a history of
schemic HF or myocardial infarction, and fewer viable myo-
ardial segments are associated with nonresponse to CRT
133–136). In addition to total scar burden, it has been shown
hat the location of scar tissue within the myocardium may play
n important role for the response to CRT, and the presence of
car in the septal (133) or posterolateral wall (136) significantly
ecreases the response rate to CRT. Finally, CMR can be used
o assess coronary venous morphology before CRT, which may
elp to determine whether the area with the greatest electrical
nd mechanical activation delay can be reached through the
enous anatomy or whether epicardial lead placement would be
ore appropriate (137).
MR for Cardiac Stem Cell Therapy
tem cell therapy aiming to repair irreversibly injured
yocardium is being intensively studied. CMR imaging
eems uniquely suited to become an integral part of this
he entire left atrium (black arrow). (B) T1-weighted turbo spin-echo image on
ve obstructing flow to the ventricle, therefore resulting in functional mitral steno-
(60 mm Hg) on echocardiography. Note also the circumferential pericardial effu-filling t
ral val
ssure
t
e
i
c
t
(
s
(
l
m
(
i
d
P
A
p
o
a
I
L
t
f
z
t
b
m
d
C
p
s
t
r
m
s
i
a
r
v
p
p
d
i
d
(
D
o
a
f
C
D
s
p
i
d
p
c
D
a
H
o
p
d
p
u
l
p
i
o
s
e
s
A
u
w
s
L
a
(
c
n
d
T
j
T
F
I
e
t
w
d
r
H
f
f
i
C
c
a
c
a
b
d
t
d
(
l
1419JACC Vol. 54, No. 15, 2009 Karamitsos et al.
October 6, 2009:1407–24 CMR in Heart Failureherapy by providing a platform to assess functional param-
ters such as LV function and size, myocardial perfusion,
nfarct size, and myocardial viability (138). Moreover, CMR
an be used for in vivo tracking of stem cells to evaluate both
heir short-term distribution and their long-term survival
138,139). Although CMR has high spatial resolution, its
ensitivity with reference to the detectable levels of tracers
105 mol/l) is relatively low compared with radioisotope-
abeled (1011 to 1012 mol/l) and optical (1015 to 1017
ol/l) imaging (139). Imaging at higher field strengths
3.0-T or higher) and the use of better labeling agents may
mprove the sensitivity of CMR to detect therapeutic cell
elivery.
rognostic Information From CMR in HF
lthough CMR, and particularly the LGE or first-pass
erfusion techniques, are relatively new imaging tools, data
n the prognostic role of CMR imaging in patients with HF
re rapidly becoming available.
schemic cardiomyopathy. Infarct size determined by
GE-CMR is a better predictor of inducible ventricular
achycardia on electrophysiological studies than LV ejection
raction (140). In addition, the extent of the peri-infarct
one assessed by CMR has been related to all-cause mor-
ality (141). Increased infarct tissue heterogeneity identified
y CMR augments the susceptibility to ventricular arrhyth-
ias in patients with prior myocardial infarction and LV
ysfunction (142). Quantification of RV ejection fraction by
MR late after myocardial infarction is an important
redictor of prognosis adjusted for patient age, LV infarct
ize, and LV ejection fraction (143). Microvascular obstruc-
ion detected by CMR predicts aggravated ventricular
emodeling and adverse cardiovascular events after acute
yocardial infarction (35). Among patients with a clinical
uspicion of CAD but without a history of myocardial
nfarction, the identification of LGE involving even a small
mount of myocardium (mean LV mass 1.4%) carries a high
isk of future cardiac events with incremental prognostic
alue beyond common clinical, angiographic, and functional
redictors (144). Finally, in patients with known or sus-
ected CAD, myocardial ischemia detected by adenosine,
ipyridamole, or dobutamine stress CMR can be used to
dentify individuals at high risk for subsequent cardiac
eath, nonfatal myocardial infarction, or congestive HF
145–147).
CM. In DCM patients with symptomatic HF, a pattern
f midwall fibrosis was associated with a high rate of
ll-cause mortality and hospitalization even after adjustment
or age, LV function, and ventricular volumes measured by
MR (148). Furthermore, adverse cardiac prognosis in
CM is associated with the presence of LGE regardless of
egmental pattern (149). Patients who had LGE of any
attern showed an 8-fold higher risk of reaching a compos-
te outcome of HF hospitalization, appropriate implantable
efibrillator discharges, and cardiac death compared with aatients without LGE. Similar to findings in ischemic
ardiomyopathy, the presence of scarring on LGE-CMR in
CM is predictive of inducible ventricular tachycardia even
fter adjustment for LV ejection fraction (150).
CM. A preliminary study in highly selected HCM patients
lder than 40 years of age showed an association between the
resence of fibrosis on LGE-CMR and the likelihood of
eveloping HF (76). More recently, it was shown that the
resence of LGE was independently associated with ventric-
lar tachyarrhythmias on an ambulatory electrocardiogram in a
argely asymptomatic or mildly symptomatic cohort of HCM
atients (151,152). LGE was associated with a 7-fold increase
n the risk of nonsustained ventricular tachycardia and was the
nly independent predictor of this arrhythmia. Further pro-
pective studies in large patient populations are required to
stablish the role of LGE as an independent predictor for
udden death or HF in HCM.
myloidosis. Recent evidence suggests that LGE carries
nique prognostic information in amyloidosis. In 29 patients
ith proven cardiac amyloidosis, LGE was associated with
ignificant survival differences (153). Moreover, the presence of
GE in patients with systemic amyloidosis is strongly associ-
ted with HF severity as assessed by B-type natriuretic peptide
154). Further confirmation from prospective studies on larger
ardiac amyloidosis cohorts is needed. The long-term prog-
ostic implications of LGE in cardiac sarcoidosis and myocar-
itis have yet to be determined.
halassemia. Recent evidence suggests that thalassemia ma-
or patients with heavy myocardial iron overload (myocardial
2* 10 ms) have a high risk of developing HF (155).
uture Perspective
t is anticipated that the application of CMR in the
valuation of patients with HF will expand substantially in
he coming years. We predict that most patients with HF
ill eventually undergo CMR imaging as part of the
iagnostic workup and to guide management and stratify
isk. The list of proposed indications for the use of CMR in
F patients (Table 1) is likely to further expand in the near
uture (156). Improvement in software and hardware will
urther shorten scan times and allow the use of real-time
maging with better spatial and temporal resolution. New
MR techniques aiming at the identification and quantifi-
ation of diffuse fibrosis will further improve the in vivo
ssessment of myocardial pathology (157). Novel CMR
ontrast agents will target specific tissue types for diagnosis
nd treatment. Stem cell therapy will be precisely monitored
y CMR and retention of such cells by the heart will be
ocumented. Interventional CMR will be increasingly used
o guide therapeutic procedures such as closure of septal
efects or the percutaneous placement of heart valves
158–160). Finally, MR spectroscopy (a method currently
imited by its low spatial and temporal resolution) should
llow reliable assessment of metabolic changes in the failing
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etabolic therapy (161).
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APPENDIX
or accompanying Online Videos 1 and 2 and
heir legends, please see the online version of this article
